Novo Nordisk released news last week that its faster-acting fast-acting insulin has been approved by the FDA. No need for US citizens to cross the border to Canada to get it anymore!
Here’s an excerpt from the press release:
Fiasp® can be dosed at the beginning of a meal or within 20 minutes after starting a meal. Fiasp® is a new formulation of NovoLog®, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes.2 Fiasp® will be available in a pre-filled delivery device FlexTouch® pen and a 10 mL vial.1
You can read the full release here.
For more on Fiasp, here are some great resources, including Tim Street’s blog, Diabettech.com, where he shares his personal experiences of using Fiasp (along with lots of great posts on OpenAPS and Loop).